Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Vitamin D for the treatment of multiple sclerosis: a meta-analysis.

McLaughlin L, Clarke L, Khalilidehkordi E, Butzkueven H, Taylor B, Broadley SA.

J Neurol. 2018 Dec;265(12):2893-2905. doi: 10.1007/s00415-018-9074-6. Epub 2018 Oct 3. Review.

PMID:
30284038
2.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

PMID:
28550069
3.

Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia.

O'Gorman CM, Broadley SA.

J Neurol Sci. 2016 Nov 15;370:219-223. doi: 10.1016/j.jns.2016.09.057. Epub 2016 Sep 28.

PMID:
27772763
4.

Adopting genetics: motivations and outcomes of personal genomic testing in adult adoptees.

Baptista NM, Christensen KD, Carere DA, Broadley SA, Roberts JS, Green RC.

Genet Med. 2016 Sep;18(9):924-32. doi: 10.1038/gim.2015.192. Epub 2016 Jan 28.

5.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
6.

Longlook: initial outcomes of a longitudinal integrated rural clinical placement program.

Kitchener S, Day R, Faux D, Hughes M, Koppen B, Manahan D, Lennox D, Harrison C, Broadley SA.

Aust J Rural Health. 2015 Jun;23(3):169-75. doi: 10.1111/ajr.12164. Epub 2015 May 15.

PMID:
25981882
7.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. Review.

PMID:
24993136
8.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. Review.

PMID:
24993135
9.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. Review.

PMID:
24986155
10.

Smoking increases the risk of multiple sclerosis in Queensland, Australia.

O'Gorman C, Bukhari W, Todd A, Freeman S, Broadley SA.

J Clin Neurosci. 2014 Oct;21(10):1730-3. doi: 10.1016/j.jocn.2014.01.009. Epub 2014 Jun 3.

PMID:
24932591
11.

Smoking and multiple sclerosis: evidence for latitudinal and temporal variation.

O'Gorman C, Broadley SA.

J Neurol. 2014 Sep;261(9):1677-83. doi: 10.1007/s00415-014-7397-5. Epub 2014 Jun 13.

PMID:
24923244
12.

Review article: elevated troponin: diagnostic gold or fool's gold?

Rahman A, Broadley SA.

Emerg Med Australas. 2014 Apr;26(2):125-30. doi: 10.1111/1742-6723.12203. Review.

PMID:
24708000
13.

Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.

Aranha AA, Amer S, Reda ES, Broadley SA, Davoren PM.

Endocr Pract. 2013 Sep-Oct;19(5):821-8. doi: 10.4158/EP13020.RA. Review.

PMID:
23757618
14.

Multiple sclerosis: from molecules to treatment.

Broadley SA.

Int J Mol Sci. 2013 Apr 8;14(4):7598-602. doi: 10.3390/ijms14047598.

15.

Role of trigeminal microvascular decompression in the treatment of SUNCT and SUNA.

Sebastian S, Schweitzer D, Tan L, Broadley SA.

Curr Pain Headache Rep. 2013 May;17(5):332. doi: 10.1007/s11916-013-0332-0. Review.

PMID:
23564233
16.

Molecular pathogenesis of neuromyelitis optica.

Bukhari W, Barnett MH, Prain K, Broadley SA.

Int J Mol Sci. 2012 Oct 11;13(10):12970-93. doi: 10.3390/ijms131012970. Review.

17.

What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?

Buzzard KA, Broadley SA, Butzkueven H.

Int J Mol Sci. 2012 Oct 4;13(10):12665-709. doi: 10.3390/ijms131012665. Review.

18.

Modelling genetic susceptibility to multiple sclerosis with family data.

O'Gorman C, Lin R, Stankovich J, Broadley SA.

Neuroepidemiology. 2013;40(1):1-12. doi: 10.1159/000341902. Epub 2012 Oct 11. Review.

19.

The value of [18F]-fluorodeoxyglucose-positron emission tomography/CT scanning in the diagnosis of neurosarcoidosis.

Meenakshi M, Arnold C, Broadley SA.

J Clin Neurosci. 2012 Oct;19(10):1461-2. doi: 10.1016/j.jocn.2012.02.013. Epub 2012 Aug 11.

PMID:
22884221
20.

Case-control study of blink rate in Parkinson's disease under different conditions.

Fitzpatrick E, Hohl N, Silburn P, O'Gorman C, Broadley SA.

J Neurol. 2012 Apr;259(4):739-44. doi: 10.1007/s00415-011-6261-0. Epub 2011 Oct 8.

PMID:
21984191
21.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

22.

Familial recurrence risks for multiple sclerosis in Australia.

O'Gorman C, Freeman S, Taylor BV, Butzkueven H; Australian and New Zealand MS Genetics Consortium (ANZgene), Broadley SA.

J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1351-4. doi: 10.1136/jnnp.2010.233064. Epub 2011 May 7.

PMID:
21551470
23.

A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Riveros C, Mellor D, Gandhi KS, McKay FC, Cox MB, Berretta R, Vaezpour SY, Inostroza-Ponta M, Broadley SA, Heard RN, Vucic S, Stewart GJ, Williams DW, Scott RJ, Lechner-Scott J, Booth DR, Moscato P; ANZgene Multiple Sclerosis Genetics Consortium.

PLoS One. 2010 Dec 1;5(12):e14176. doi: 10.1371/journal.pone.0014176.

24.

Comparing endurance- and resistance-exercise training in people with multiple sclerosis: a randomized pilot study.

Sabapathy NM, Minahan CL, Turner GT, Broadley SA.

Clin Rehabil. 2011 Jan;25(1):14-24. doi: 10.1177/0269215510375908. Epub 2010 Aug 16.

PMID:
20713434
25.

Microvascular decompression of the trigeminal nerve in the treatment of SUNCT and SUNA.

Williams M, Bazina R, Tan L, Rice H, Broadley SA.

J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):992-6. doi: 10.1136/jnnp.2009.182824. Epub 2010 May 12.

PMID:
20462914
26.

Elevated serum concentrations of troponin T in acute stroke: what do they mean?

Ghali J, Allison D, Kleinig T, Ooi SY, Bastiampillai S, Ashby D, Taylor J, Thompson PD, Broadley SA.

J Clin Neurosci. 2010 Jan;17(1):69-73. doi: 10.1016/j.jocn.2009.03.017. Epub 2009 Oct 29.

PMID:
19879148
27.

The role of molecular chaperones in human misfolding diseases.

Broadley SA, Hartl FU.

FEBS Lett. 2009 Aug 20;583(16):2647-53. doi: 10.1016/j.febslet.2009.04.029. Epub 2009 Apr 23. Review.

28.

Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis.

Broadley SA, Vanags D, Williams B, Johnson B, Feeney D, Griffiths L, Shakib S, Brown G, Coulthard A, Mullins P, Kneebone C.

Mult Scler. 2009 Mar;15(3):329-36. doi: 10.1177/1352458508099141. Epub 2008 Nov 27.

PMID:
19039022
29.

N-terminal polyglutamine-containing fragments inhibit androgen receptor transactivation function.

Schiffer NW, Céraline J, Hartl FU, Broadley SA.

Biol Chem. 2008 Dec;389(12):1455-66. doi: 10.1515/BC.2008.169.

PMID:
18844449
30.

SUNCT and SUNA: clinical features and medical treatment.

Williams MH, Broadley SA.

J Clin Neurosci. 2008 May;15(5):526-34. doi: 10.1016/j.jocn.2006.09.006. Epub 2008 Mar 5.

PMID:
18325769
31.

Mitochondrial stress signaling: a pathway unfolds.

Broadley SA, Hartl FU.

Trends Cell Biol. 2008 Jan;18(1):1-4. Epub 2007 Dec 18.

PMID:
18068368
32.

Translocation of mitochondrially synthesized Cox2 domains from the matrix to the intermembrane space.

Fiumera HL, Broadley SA, Fox TD.

Mol Cell Biol. 2007 Jul;27(13):4664-73. Epub 2007 Apr 23.

33.

Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model.

Schiffer NW, Broadley SA, Hirschberger T, Tavan P, Kretzschmar HA, Giese A, Haass C, Hartl FU, Schmid B.

J Biol Chem. 2007 Mar 23;282(12):9195-203. Epub 2006 Dec 14.

34.

Early investigation and treatment of obstructive sleep apnoea after acute stroke.

Broadley SA, Jørgensen L, Cheek A, Salonikis S, Taylor J, Thompson PD, Antic R.

J Clin Neurosci. 2007 Apr;14(4):328-33. Epub 2006 Jun 21.

PMID:
16790349
35.

Molecular chaperones of the Hsp110 family act as nucleotide exchange factors of Hsp70s.

Dragovic Z, Broadley SA, Shomura Y, Bracher A, Hartl FU.

EMBO J. 2006 Jun 7;25(11):2519-28. Epub 2006 May 11.

36.

Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.

Haacke A, Broadley SA, Boteva R, Tzvetkov N, Hartl FU, Breuer P.

Hum Mol Genet. 2006 Feb 15;15(4):555-68. Epub 2006 Jan 11.

PMID:
16407371
37.

Unusual cause of sudden onset headache: spontaneous intracranial hypotension.

Broadley SA, Park N, Renowden S, Ferguson IT.

Emerg Med Australas. 2005 Oct-Dec;17(5-6):520-3.

PMID:
16302946
38.

Roles of molecular chaperones in protein misfolding diseases.

Barral JM, Broadley SA, Schaffar G, Hartl FU.

Semin Cell Dev Biol. 2004 Feb;15(1):17-29. Review.

PMID:
15036203
39.

Mss51p promotes mitochondrial Cox1p synthesis and interacts with newly synthesized Cox1p.

Perez-Martinez X, Broadley SA, Fox TD.

EMBO J. 2003 Nov 3;22(21):5951-61.

40.

Time to hospital admission for acute stroke: an observational study.

Broadley SA, Thompson PD.

Med J Aust. 2003 Apr 7;178(7):329-31.

PMID:
12670275
41.

The clinical and MRI correlate of ischaemia in the ventromedial midbrain: Claude's syndrome.

Broadley SA, Taylor J, Waddy HM, Thompson PD.

J Neurol. 2001 Dec;248(12):1087-9.

PMID:
12013587
43.

No association between multiple sclerosis and the Notch3 gene responsible for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).

Broadley SA, Sawcer SJ, Chataway SJ, Coraddu F, Coles A, Gray J, Roxburgh R, Clayton D, Compston DA.

J Neurol Neurosurg Psychiatry. 2001 Jul;71(1):97-9.

44.

Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey.

Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA.

Brain. 2000 Jun;123 ( Pt 6):1102-11.

PMID:
10825350
45.

Multiple sclerosis and tonsillectomy: no evidence for an influence on the development of disease or clinical phenotype.

Broadley SA, Deans J, Chataway SJ, Sawcer SJ, Compston DA.

Mult Scler. 2000 Apr;6(2):121-3.

PMID:
10773858
46.

Lumbar puncture needn't be a headache.

Broadley SA, Fuller GN.

BMJ. 1997 Nov 22;315(7119):1324-5. No abstract available.

47.

Severe sensorimotor polyradiculoneuropathy after ingestion of ethylene glycol.

Broadley SA, Ferguson IT, Walton B, Tomson CR.

J Neurol Neurosurg Psychiatry. 1997 Aug;63(2):261. No abstract available.

Supplemental Content

Loading ...
Support Center